|
|
 |
|
Viewing report
|
|
|
|
Psychiatric Drugs: New Developments and Market Analysis by Drug Class and Clinical Indication
Drug and Market Development Publishing, Nov 2004, Pages: 250
The principal emphasis and organization of this report is based on drug class/mechanism of action, which is covered in:
Chapter 2: Drug Class Analysis. This section profiles cutting edge drug development in ten major psychiatric drug classes. It includes up to date tables of drugs in development and focuses on important R&D trends and includes analysis of critical upcoming developments (e.g., approvals and patent expirations), markets, and market drivers. Reference is made to relevant clinical indications, which are profiled in Chapter 3. The overall structure reflects the multiple applications of many psychiatric drug classes (with minimal redundancy).
Chapter 3: Clinical Markets. This section profiles nine major psychiatric indications, including clinical indications, including basic definitions, etiology (covered in chapters 2 and 3), prevalence estimates, and current therapy. Reference is made to relevant drug classes (and in some cases markets) addressed in Chapter 2.
Chapter 4: Company Profiles. This section provides listings of drug development underway by 58 companies appearing in this report. Company involvement in psychiatric drug development range from small companies developing only a few drugs to major pharmaceutical companies developing a dozen to more than 20 drugs for psychiatric indications (e.g., GlaxoSmithKline, Eli Lilly, Pfizer, Roche, Sanofi-Aventis). This chapter is focused exclusively on drug development efforts for psychiatric indications. Contact information is provided.
Customers who bought this item also bought
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Pharmacogenomics for Clinical Use and in Drug Development
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
Emerging Diagnostic Technologies for Use in Psychiatric Indications
Pain Therapeutics - Drugs, Markets and Companies
Anxiety Disorders - A Decade of Declining Revenues
Infectious Diseases Drugs Markets
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Neuroprotection - Drugs, Markets and Companies
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Handbook of Psychiatric Drugs
Drugs in the Pipeline--An R&D Analysis
|
|
|
|
